UNSPSC 51284302: Florfenicol

This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C12H14Cl2FNO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J97307Y1H, chemically known as 2,2-dichloro-n-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)acetamide but generally known as florfenicol, which bears US NIH Compound Identifier 114811. European Medicines Agency schedules Florfenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07651MIG.

UNSPSC 51284302 Florfenicol, a Commodity code, does not align with the recent state and local solicitations tagged under it. The code nominally covers a specific veterinary antibiotic, but the four recent opportunities posted in 2026 solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which are florfenicol or closely related veterinary pharmaceuticals. This mismatch suggests the code has been misapplied to these opportunities or that state and local procurement systems are using the code as a catch-all for pharmaceutical and medical supply procurement without precise commodity alignment.

The issuing bodies span county health departments, state human services commissions, municipal fire departments, and cooperative purchasing alliances across Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023); the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026); the City of Tampa Fire Department's sealed bid for 169 line items of medical and first aid supplies with an estimated contract value of $700,000.00 and a 5% SLBE bid discount (due March 13, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (due March 26, 2026). The code shows recent activity but lacks authentic florfenicol procurement signals; buyers pursuing this code should verify whether their target jurisdictions are sourcing actual florfenicol or whether tagging reflects system misconfiguration rather than genuine demand.